Literature DB >> 26269629

The Parkinson's Disease-Associated Mutation LRRK2-G2019S Impairs Synaptic Plasticity in Mouse Hippocampus.

Eric S Sweet1, Bernadette Saunier-Rebori2, Zhenyu Yue3, Robert D Blitzer4.   

Abstract

Parkinson's disease (PD) is a major movement disorder characterized by the loss of dopamine neurons and formation of Lewy bodies. Clinical and pathological evidence indicates that multiple brain regions are affected in PD in a spatiotemporal manner and are associated with a variety of motor and nonmotor symptoms, including disturbances in mood, executive function, and memory. The common PD-associated gene for leucine-rich repeat kinase, leucine-rich repeat kinase 2 (LRRK2), is highly expressed in brain regions that are involved with nonmotor functions, including the neocortex and hippocampus, but whether mutant LRRK2 contributes to neuronal dysfunction in these regions is unknown. Here, we use bacterial artificial chromosome transgenic mouse models of LRRK2 to explore potential nonmotor mechanisms of PD. Through electrophysiological analysis of the Schaffer collateral-CA1 synapse in dorsal hippocampus, we find that overexpression of LRRK2-G2019S increases basal synaptic efficiency through a postsynaptic mechanism, and disrupts long-term depression. Furthermore, these effects of the G2019S mutation are age dependent and can be normalized by acute inhibition of LRRK2 kinase activity. In contrast, overexpression of wild-type LRRK2 has no effect under the same conditions, suggesting a specific phenotype for the G2019S mutation. These results identify a pathogenic function of LRRK2 in the hippocampus that may contribute to nonmotor symptoms of PD. SIGNIFICANCE STATEMENT: Parkinson's disease (PD) is among the most common neurological diseases and is best known for its adverse effects on brain regions that control motor function, resulting in tremor, rigidity, and gait abnormalities. Less well appreciated are the psychiatric symptoms experienced by many PD patients, including depression and memory loss, which do not respond well to currently available treatments for PD. Here, we describe functional effects of a common PD-linked mutation of leucine-rich repeat kinase 2 in the mouse hippocampus, an area of the brain that is responsible for encoding and retaining memories. By providing a potential mechanism for some of the cognitive symptoms produced by this mutation, our findings may lead to novel approaches for the treatment of nonmotor symptoms of PD.
Copyright © 2015 the authors 0270-6474/15/3511190-06$15.00/0.

Entities:  

Keywords:  LRRK2; aged; electrophysiology; long-term depression; nonmotor deficits; transgenic

Mesh:

Substances:

Year:  2015        PMID: 26269629      PMCID: PMC4532754          DOI: 10.1523/JNEUROSCI.0040-15.2015

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  32 in total

1.  LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis.

Authors:  Samer Matta; Kristof Van Kolen; Raquel da Cunha; Geert van den Bogaart; Wim Mandemakers; Katarzyna Miskiewicz; Pieter-Jan De Bock; Vanessa A Morais; Sven Vilain; Dominik Haddad; Lore Delbroek; Jef Swerts; Lucía Chávez-Gutiérrez; Giovanni Esposito; Guy Daneels; Eric Karran; Matthew Holt; Kris Gevaert; Diederik W Moechars; Bart De Strooper; Patrik Verstreken
Journal:  Neuron       Date:  2012-09-20       Impact factor: 17.173

2.  LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool.

Authors:  Giovanni Piccoli; Steven B Condliffe; Matthias Bauer; Florian Giesert; Karsten Boldt; Silvia De Astis; Andrea Meixner; Hakan Sarioglu; Daniela M Vogt-Weisenhorn; Wolfgang Wurst; Christian Johannes Gloeckner; Michela Matteoli; Carlo Sala; Marius Ueffing
Journal:  J Neurosci       Date:  2011-02-09       Impact factor: 6.167

3.  Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S.

Authors:  Xianting Li; Jyoti C Patel; Jing Wang; Marat V Avshalumov; Charles Nicholson; Joseph D Buxbaum; Gregory A Elder; Margaret E Rice; Zhenyu Yue
Journal:  J Neurosci       Date:  2010-02-03       Impact factor: 6.167

4.  LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity.

Authors:  Loukia Parisiadou; Jia Yu; Carmelo Sgobio; Chengsong Xie; Guoxiang Liu; Lixin Sun; Xing-Long Gu; Xian Lin; Nicole A Crowley; David M Lovinger; Huaibin Cai
Journal:  Nat Neurosci       Date:  2014-01-26       Impact factor: 24.884

5.  Mutant LRRK2 enhances glutamatergic synapse activity and evokes excitotoxic dendrite degeneration.

Authors:  Edward D Plowey; Jon W Johnson; Erin Steer; Wan Zhu; David A Eisenberg; Natalie M Valentino; Yong-Jian Liu; Charleen T Chu
Journal:  Biochim Biophys Acta       Date:  2014-05-27

6.  Effect of mild cognitive impairment on the patterns of neural activity in early Parkinson's disease.

Authors:  Atsuko Nagano-Saito; Claudine Habak; Beatriz Mejía-Constaín; Clotilde Degroot; Laura Monetta; Thomas Jubault; Christophe Bedetti; Anne-Louise Lafontaine; Sylvain Chouinard; Valérie Soland; Alain Ptito; Antonio P Strafella; Oury Monchi
Journal:  Neurobiol Aging       Date:  2013-08-07       Impact factor: 4.673

7.  The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years.

Authors:  Mariese A Hely; Wayne G J Reid; Michael A Adena; Glenda M Halliday; John G L Morris
Journal:  Mov Disord       Date:  2008-04-30       Impact factor: 10.338

8.  Essential functions of synapsins I and II in synaptic vesicle regulation.

Authors:  T W Rosahl; D Spillane; M Missler; J Herz; D K Selig; J R Wolff; R E Hammer; R C Malenka; T C Südhof
Journal:  Nature       Date:  1995-06-08       Impact factor: 49.962

9.  Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations.

Authors:  Roy N Alcalay; Anat Mirelman; Rachel Saunders-Pullman; Ming-X Tang; Helen Mejia Santana; Deborah Raymond; Ernest Roos; Martha Orbe-Reilly; Tanya Gurevich; Anat Bar Shira; Mali Gana Weisz; Kira Yasinovsky; Maayan Zalis; Avner Thaler; Andres Deik; Matthew James Barrett; Jose Cabassa; Mark Groves; Ann L Hunt; Naomi Lubarr; Marta San Luciano; Joan Miravite; Christina Palmese; Rivka Sachdev; Harini Sarva; Lawrence Severt; Vicki Shanker; Matthew Carrington Swan; Jeannie Soto-Valencia; Brooke Johannes; Robert Ortega; Stanley Fahn; Lucien Cote; Cheryl Waters; Pietro Mazzoni; Blair Ford; Elan Louis; Oren Levy; Llency Rosado; Diana Ruiz; Tsvyatko Dorovski; Michael Pauciulo; William Nichols; Avi Orr-Urtreger; Laurie Ozelius; Lorraine Clark; Nir Giladi; Susan Bressman; Karen S Marder
Journal:  Mov Disord       Date:  2013-10-15       Impact factor: 10.338

10.  A direct interaction between leucine-rich repeat kinase 2 and specific β-tubulin isoforms regulates tubulin acetylation.

Authors:  Bernard M H Law; Victoria A Spain; Veronica H L Leinster; Ruth Chia; Alexandra Beilina; Hyun J Cho; Jean-Marc Taymans; Mary K Urban; Rosa M Sancho; Marian Blanca Ramírez; Saskia Biskup; Veerle Baekelandt; Huaibin Cai; Mark R Cookson; Daniel C Berwick; Kirsten Harvey
Journal:  J Biol Chem       Date:  2013-11-25       Impact factor: 5.157

View more
  31 in total

Review 1.  Functional and behavioral consequences of Parkinson's disease-associated LRRK2-G2019S mutation.

Authors:  Deanna L Benson; Bridget A Matikainen-Ankney; Ayan Hussein; George W Huntley
Journal:  Biochem Soc Trans       Date:  2018-12-04       Impact factor: 5.407

2.  Mitochondrial Calcium Dysregulation Contributes to Dendrite Degeneration Mediated by PD/LBD-Associated LRRK2 Mutants.

Authors:  Manish Verma; Jason Callio; P Anthony Otero; Israel Sekler; Zachary P Wills; Charleen T Chu
Journal:  J Neurosci       Date:  2017-10-16       Impact factor: 6.167

3.  Human LRRK2 G2019S mutation represses post-synaptic protein PSD95 and causes cognitive impairment in transgenic mice.

Authors:  Samuel O Adeosun; Xu Hou; Baoying Zheng; Heather L Melrose; Thomas Mosley; Jun Ming Wang
Journal:  Neurobiol Learn Mem       Date:  2017-05-06       Impact factor: 2.877

4.  Protective effects of curcumin against rotenone-induced rat model of Parkinson's disease: in vivo electrophysiological and behavioral study.

Authors:  L V Darbinyan; L E Hambardzumyan; K V Simonyan; V A Chavushyan; L P Manukyan; S A Badalyan; N Khalaji; V H Sarkisian
Journal:  Metab Brain Dis       Date:  2017-07-10       Impact factor: 3.584

5.  LRRK2 and GBA Variants Exert Distinct Influences on Parkinson's Disease-Specific Metabolic Networks.

Authors:  Katharina A Schindlbeck; An Vo; Nha Nguyen; Chris C Tang; Martin Niethammer; Vijay Dhawan; Vicky Brandt; Rachel Saunders-Pullman; Susan B Bressman; David Eidelberg
Journal:  Cereb Cortex       Date:  2020-05-14       Impact factor: 5.357

6.  LRRK2 plays essential roles in maintaining lung homeostasis and preventing the development of pulmonary fibrosis.

Authors:  Yujie Tian; Jiaoyan Lv; Ziyan Su; Tao Wu; Xiaoguang Li; Xiaoyu Hu; Jianhong Zhang; Li Wu
Journal:  Proc Natl Acad Sci U S A       Date:  2021-08-31       Impact factor: 11.205

7.  A quantitative systems pharmacology model for simulating OFF-Time in augmentation trials for Parkinson's disease: application to preladenant.

Authors:  Rachel Rose; Emma Mitchell; Piet Van Der Graaf; Daisuke Takaichi; Jun Hosogi; Hugo Geerts
Journal:  J Pharmacokinet Pharmacodyn       Date:  2022-10-09       Impact factor: 2.410

Review 8.  Are we listening to everything the PARK genes are telling us?

Authors:  Deanna L Benson; George W Huntley
Journal:  J Comp Neurol       Date:  2019-02-08       Impact factor: 3.215

9.  Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation.

Authors:  Bridget A Matikainen-Ankney; Nebojsa Kezunovic; Roxana E Mesias; Yuan Tian; Frances M Williams; George W Huntley; Deanna L Benson
Journal:  J Neurosci       Date:  2016-07-06       Impact factor: 6.167

10.  Non-Motor Symptoms of Parkinson's Disease: The Neurobiology of Early Psychiatric and Cognitive Dysfunction.

Authors:  Ayan Hussein; Christopher A Guevara; Pamela Del Valle; Swati Gupta; Deanna L Benson; George W Huntley
Journal:  Neuroscientist       Date:  2021-05-08       Impact factor: 7.235

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.